Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery.
As the pharmaceuticals industry turns its attention to precision medicine the search for ever more tailored treatments for specific diseases using genetic engineering Octant is using the same technologies to engage in drug discovery and diagnostics on a mass scale.
The companys technology genetically engineers DNA to act as an identifier for the most common drug receptors inside the human genome. Basically, its creating QR codes that can flag and identify how different protein receptors in cells respond to chemicals. These are the biological sensors which help control everything from immune responses to the senses of sight and smell, the firing of neurons; even the release of hormones and communications between cells in the body are regulated.
Our discovery platform was designed to map and measure the interconnected relationships between chemicals, multiple drug receptor pathways and diseases, enabling us to engineer multi-targeted drugs in a more rational way, across a wide spectrum of targets, said Sri Kosuri, Octants co-founder and chief executive officer, in a statement.
Octants work is based on a technology first developed at the University of California Los Angeles by Kosuri and a team of researchers, which slashed the cost of making genetic sequences to $2 per gene from $50 to $100 per gene.
Our method gives any lab that wants the power to build its own DNA sequences, Kosuri said in a 2018 statement. This is the first time that, without a million dollars, an average lab can make 10,000 genes from scratch.
Joining Kosuri in launching Octant is Ramsey Homsany, a longtime friend of Kosuris, and a former executive at Google and Dropbox . Homsany happened to have a background in molecular biology from school, and when Kosuri would talk about the implications of the technology he developed, the two men knew they needed to for a company.
We use these new tools to know which bar code is going with which construct or genetic variant or pathway that were working with [and] all of that fits into a single well, said Kosuri. What you can do on top of that is small molecule screening we can do that with thousands of different wells at a time. So we can build these maps between chemicals and targets and pathways that are essential to drug development.
Before coming to UCLA, Kosuri had a long history with companies developing products based on synthetic biology on both the coasts. Through some initial work that hed done in the early days of the biofuel boom in 2007, Kosuri was connected with Flagship Ventures, and the imminent Harvard-based synthetic biologist George Church . He also served as a scientific advisor to Gen9, a company acquired by the multi-billion dollar synthetic biology powerhouse, Ginkgo Bioworks.
Some of the most valuable drugs in history work on complex sets of drug targets, which is why Octants focus on polypharmacology is so compelling, said Jason Kelly, the co-founder and CEO of Gingko Bioworks, and a member of the Octant board, in a statement. Octant is engineering a lot of luck and cost out of the drug discovery equation with its novel platform and unique big data biology insights, which will drive the companys internal development programs as well as potential partnerships.
The new technology arrives at a unique moment in the industry where pharmaceutical companies are moving to target treatments for diseases that are tied to specific mutations, rather than look at treatments for more common disease problems, said Homsany.
People are dropping common disease problems, he said. The biggest players are dropping these cases and it seems like that just didnt make sense to us. So we thought about how would a company take these new technologies and apply them in a way that could solve some of this.
One reason for the industrys turn away from the big diseases that affect large swaths of the population is that new therapies are emerging to treat these conditions which dont rely on drugs. While they wouldnt get into specifics, Octant co-founders are pursuing treatments for what Kosuri said were conditions in the metabolic space and in the neuropsychiatric space.
Helping them pursue those targets, since Octant is very much a drug development company, is $30 million in financing from investors led by Andreessen Horowitz .
Drug discovery remains a process of trial and error. Using its deep expertise in synthetic biology, the Octant team has engineered human cells that provide real-time, precise and complete readouts of the complex interactions and effects that drug molecules have within living cells, said Jorge Conde, general partner at Andreessen Horowitz, and member of the Octant board of directors. By querying biology at this unprecedented scale, Octant has the potential to systematically create exhaustive maps of drug targets and corresponding, novel treatments for our most intractable diseases.
- Lords seek to allow gene-editing in UK 'to produce healthy, hardier crops' - The Guardian - June 20th, 2020
- Ginkgo Bioworks CEO on scaling up Covid-19 testing: 'If we try, we can win' - CNBC - June 20th, 2020
- GlobalGenome Engineering Market Report 2020 Sales Forecast to Grow Negatively in Western Regio post COVID 19 Impact Analysis Updated Edition Top... - June 20th, 2020
- Coronavirus vaccines are coming, but when will they arrive? - Digital Journal - June 20th, 2020
- Swiss men aspire to live to 108.5 years old - MENAFN.COM - June 20th, 2020
- Bioengineered Protein Drugs Market Professional Survey 2020 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2026 -... - June 20th, 2020
- Texas A&M Researcher Creating Better Corn Yields, Quality On Less Land - Texas A&M University Today - June 20th, 2020
- Annecy Pitches: 5 Film Projects That Caught Our Eye - Cartoon Brew - June 20th, 2020
- Italy and Israel bet on GM microalgae to develop edible COVID vaccine - Alliance for Science - June 13th, 2020
- GM seeds: the debate, and a sowing agitation - The Indian Express - June 13th, 2020
- Viral Vector and Plasmid DNA Testing Services Market Players focusing on the invention of new techniques in a bid to better the characterization of... - June 13th, 2020
- What scientists are learning about COVID-19 from animals - WISHTV.com - June 13th, 2020
- How Receptive are Consumers to Agricultural Biotech? - Food Institute Focus - Food Institute Blog - June 13th, 2020
- Egg-based coating preserves fresh produce - Feedstuffs - June 13th, 2020
- Fat alternative Epogee gains traction: 'The low-fat ship sailed 25 years ago, this is not about low fat, it's about caloric reduction' -... - June 13th, 2020
- CRISPR-Based Therapeutics Market with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast - Cole of Duty - June 13th, 2020
- Gene Therapy and Editing : Novel options for inherited retinal blindness - ETHealthworld.com - June 13th, 2020
- Fat cells remember their diets early in life - Massive Science - June 13th, 2020
- Researchers find new selective-breeding method for heat-tolerant abalone without genetic modification - Aju Business Daily - May 29th, 2020
- Ethicists: We need more flexible tools for evaluating gene-edited food - The Conversation US - May 29th, 2020
- On the Origins of Modern Biology and the Fantastic: Part 18 Nalo Hopkinson and Stem Cell Research - tor.com - May 29th, 2020
- global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030 - Salamanca... - May 29th, 2020
- COVID-19: Responding to the business impacts of CRISPR And CRISPR-Associated (Cas) Genes Market 2019 Trends, Size, Segments, Emerging Technologies and... - May 29th, 2020
- Astronauts can change DNA for the colonization of Mars - The Times Hub - May 29th, 2020
- Potential impact of coronavirus outbreak on Zinc Finger Nuclease Technology Market: Opportunities and Forecast Assessment, 2019-2027 - Jewish Life... - May 29th, 2020
- Genes linked to evolution of languages - Cosmos - May 29th, 2020
- Global Food Enzymes Market (2020 to 2025) - Recent Innovations in the Market - GlobeNewswire - May 29th, 2020
- The impact of the coronavirus on the Genetic Engineering Market Solid Analyzed Segmentation, Demand, Recent Share Estimation and Growth Prospects by... - May 24th, 2020
- One of the World's Most Powerful Scientists Believes in Miracles - Scientific American - May 24th, 2020
- COVID-19 Vaccines: A Reason to Hope We're Flying Blind No More - The Wire - May 24th, 2020
- Humans will be able to replace their bodies within 50 years claims transhumanist writer - Express.co.uk - May 24th, 2020
- Menu of solutions, no silver bullet, to feed the world - FeedStrategy.com - May 24th, 2020
- Emerging courses: How to become a healthcare engineer - The Indian Express - May 24th, 2020
- Why Italians aren't all the same - Cosmos - May 24th, 2020
- Coronavirus: Parliament told there is 'no evidence' virus came from Wuhan laboratory - Sky News - May 24th, 2020
- Yeast fermentation may be the answer to creating rare cannabinoids - Leafly - May 24th, 2020
- Climate change and coronavirus: Is the Covid-19 pandemic really a surprise? - DailyO - May 24th, 2020
- Dyno Debuts With Plan, Partnerships For Better Gene Therapy Vectors - Xconomy - May 11th, 2020
- Your genes could determine whether the coronavirus puts you in the hospital and we're starting to unravel which ones matter - The Conversation US - May 11th, 2020
- How Covid-19 Can Save the World's Bee Population - CTech - May 11th, 2020
- B-P names Top 10 students in Class of 2020 - The Recorder - May 11th, 2020
- Whether the Coronavirus Puts You in the Hospital Could Depend on Your Genes And Were Unraveling Which Ones Matter - SciTechDaily - May 11th, 2020
- Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.... - May 11th, 2020
- Researchers Develop New Classification Tool to Find COVID-19 Genetic Signature - ENGINEERING.com - May 11th, 2020
- Covid-19: What you need to know today - Hindustan Times - May 11th, 2020
- Exercise may help reduce the risk of deadly COVID-19 complication - GOOD Magazine - May 11th, 2020
- Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops - ScienceAlert - May 4th, 2020
- This Week's Awesome Tech Stories From Around the Web (Through May 2) - Singularity Hub - May 4th, 2020
- The Pandemic and America's Response to Future Bioweapons - War on the Rocks - May 4th, 2020
- Blue-sky thinking for food production - Farm Weekly - May 4th, 2020
- The pieces of the puzzle of covid-19s origin are coming to light - The Economist - May 4th, 2020
- Merck & Co. Partnering with ISB to Study Targets for COVID-19 Therapeutics - Genetic Engineering & Biotechnology News - May 4th, 2020
- The next pandemic could be even worse - CNN - May 4th, 2020
- We need more honesty in GMO discussions - Ethiopia Observer - May 4th, 2020
- Covid-19 treatment on the horizon but vaccine remains elusive - Pharmaceutical Technology - May 4th, 2020
- Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies -... - May 4th, 2020
- Better Predicting the Unpredictable Byproducts of Genetic Modification - NC State News - April 11th, 2020
- Fiction about pandemics and dystopian future - Dhaka Tribune - April 11th, 2020
- David Lynch believes the world will be a more spiritual, much kinder place after lockdown ends - Far Out Magazine - April 11th, 2020
- Tension Builds Over Drug To Treat COVID-19 - caribbeannationalweekly.com - April 11th, 2020
- Disease is the greatest threat to bee health. Can we protect them through genetically engineered probiotics? - Genetic Literacy Project - April 9th, 2020
- CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic - P&T Community - April 9th, 2020
- CAR T-Cell Therapy for Multiple Myeloma - Global Market Insights and Market Forecast to 2030 - ResearchAndMarkets.com - Yahoo Finance - April 9th, 2020
- One in four Britons 'think the coronavirus was probably created in a lab' - Yahoo Sports - April 9th, 2020
- Fear of global plagues and greed for money are as old as mankind - SowetanLIVE - April 9th, 2020
- CRISPR gene editing could yield drought-tolerant tomatoes and kiwis that grow in salty soil - Genetic Literacy Project - March 31st, 2020
- How the novel coronavirus is mutating, and if you should be concerned - ThePrint - March 31st, 2020
- India What we know about the genome of the virus in India A mutation unique to - Times of India - March 31st, 2020
- Why can't we have a COVID-19 vaccine right now? - OnCubaNews - March 31st, 2020
- Column: Roswell Park's alliance with Cuba gets the 'wow' treatment from PBS' 'Nova' - Buffalo News - March 31st, 2020
- Scientist says anti-epilepsy drug can be repurposed for Covid-19, writes to ICMR to test it - ThePrint - March 31st, 2020
- Treatment gets five out of Intensive Care - Dominican Today - March 31st, 2020
- Cannabis Compound CBD Acts as Helper to Boost Antibiotic Effectiveness - Genetic Engineering & Biotechnology News - March 31st, 2020
- A Bioweapon Or Effects Of 5G? 7 Conspiracy Theories Around Coronavirus That Will Shock You - The Biggest Humanitarian Crisis - Economic Times - March 31st, 2020
- Is the Indian COVID-19 strain weaker? - Times of India - March 26th, 2020
- Timeline Shows 3 Paths To COVID-19 Treatment And Prevention (INFOGRAPHIC) - Forbes - March 26th, 2020
- This Fulbright scholar wants to find ways to prevent or slow the spread of cancer - News@Northeastern - March 26th, 2020
- Covid 19: HOMEF Cautions On Use of Biodiversity - Leadership Newspaper - March 26th, 2020
- Genetically targeted chemical assembly of functional materials in living cells, tissues, and animals - Science Magazine - March 25th, 2020
- What Anti-Science Activists And Lawyers Have In Common During This Crisis They Share The Rest Of The Time: Fear Profiteering - Science 2.0 - March 25th, 2020